Components for drug delivery devices

By designing encoded information features on the housing unit and cap of the drug delivery device to distinguish the prepared distribution and assigned states, the problem that drug delivery devices in the prior art is difficult to quickly and accurately distinguish the usage states, and the safety is improved and evaluate efficiency.

CN113924136BActive Publication Date: 2024-11-05SANOFI SA(FR)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080038369.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-04-04
Filing Date
2020-04-01
Publication Date
2024-11-05
Estimated Expiration
2040-04-01

AI Technical Summary

Technical Problem

Existing drug delivery devices are difficult to quickly and accurately distinguish whether they have been used, resulting in inefficient safety and evaluation, increasing the risk of incorrect evaluation and reuse.

Method used

An assembly is designed including a housing unit and a cap that has encoded information features that cover or expose when connected and disconnected, distinguishing between pre-allocated and assigned states by machine readability and visibility. , reduce the risk of reuse.

Benefits of technology

The rapid and accurate detection of the use status of the drug delivery device through distinct visible and machine-readable information features significantly reduces the risk of attempting or reusing in assigned conditions, and improves safety and evaluation efficiency.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113924136B_ABST
    Figure CN113924136B_ABST
Patent Text Reader

Abstract

A component (1) for a drug delivery device, the component (1) comprising: a housing unit (2) for receiving a reservoir and a dispensing mechanism configured to dispense liquid drug contents from the reservoir during a dispensing operation; a cap (3) releasably connected to the housing unit (2); a first information feature (4) having a first encoded content; a second information feature (5), wherein the first information feature (4) is visible and / or machine-readable when the cap (3) is connected to the housing unit (2) and can be removed from the housing unit (2) or become unreadable together with the cap (3) when the cap (3) is disconnected from the housing unit (2), and wherein the dispensing mechanism has two different states, namely a first state in which the dispensing mechanism is in a ready-to-dispense state and a second state in which the dispensing mechanism is in a dispensed state, wherein the second information feature (5) is invisible in the first state and visible in the second state.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to an assembly, for example for a drug delivery device. Background Art

[0002] Mobile or portable drug delivery devices are often used in emergency situations, where there is little time to administer a conserved amount of medication to the patient. Another common use is self-administration by patients (e.g., patients without medical training). Therefore, unintentional use of a used drug delivery device can have devastating consequences for the patient's health. Therefore, it is desirable to provide drug delivery devices that can clearly distinguish between used and unused situations due to their appearance.

[0003] Drug delivery devices are known in the prior art, where it can be determined by an in-depth study of the appearance whether the drug delivery device has been used. Sometimes, the researcher must visually inspect a remote or small feature area of ​​the device to verify whether the device has been used. However, even such drug delivery devices have little safety. Since the evaluation of such drug delivery devices is very time-consuming, especially when the number of drug delivery devices is large, the research may quickly tire the researcher entrusted with the evaluation, which of course will inevitably increase the risk of incorrect evaluation by the researcher. Summary of the invention

[0004] It is an object of the present invention to provide an improved assembly for a drug delivery device. Preferably, an assembly should be provided which facilitates the assessment of whether the device has been potentially used.

[0005] According to the present invention, there is provided an assembly for a drug delivery device, the assembly comprising: a housing unit, the housing unit comprising a housing for receiving a reservoir and a dispensing mechanism configured to dispense liquid drug contents from the reservoir in a dispensing operation; a cap releasably connected to the housing unit, the cap at least partially covering a distal dispensing end of the assembly when connected to the housing unit, wherein the distal dispensing end is not covered when the cap is disconnected from the housing unit. The cap can be connected to the housing of the housing unit, for example, by a snap feature. The assembly also comprises a first information feature having an encoded first content, wherein the first information feature is machine readable to retrieve the first content from the first information feature. The assembly may comprise a second information feature, for example, machine readable. The first information feature is visible and / or machine readable when the cap is connected to the housing unit and can be removed from the housing unit together with the cap or become unreadable when the cap is disconnected from the housing unit. The dispensing mechanism has two different states, namely a first state in which the dispensing mechanism is in a ready-to-dispense condition and a second state in which the dispensing mechanism is in a dispensed condition. The second information feature is not visible in the first state and is visible in the second state. The assembly may be a drug delivery device. If the reservoir is arranged in the housing, the assembly may be a drug delivery device ready to dispense the contents of the reservoir from the device. In the assembly, the reservoir may or may not be received in the housing. The reservoir may be a syringe, such as a prefilled syringe.

[0006] In the context of the present disclosure, the term "distal dispensing end" may refer to an end region of a component that is directed toward or designed to abut a target surface (e.g., a skin portion of a patient) during a dispensing operation. The term "dispensing operation" may refer to a process performed by a dispensing mechanism to conveniently dispense a drug from a reservoir of a component via operation of the dispensing mechanism. The drug may be applied, for example, via a needle to an area beneath the patient's skin. The dispensing mechanism may be spring-driven. The drug delivery device may be a disposable device that is disposed of after the reservoir has been emptied. The device may be a single-use device that is disposed of after performing only a single dispensing operation for dispensing one dose.

[0007] In the context of the present disclosure, the term "ready to dispense condition" may refer to the condition of the assembly before a dispensing operation has been started or initiated. In this condition, the reservoir may or may not be arranged in the housing. In the latter case, the dispensing mechanism performs the motion required for the dispensing operation, but does not dispense liquid medicine from the device.

[0008] In the context of the present disclosure, the term "dispensed state" may refer to a state after a dispensing operation (preferably after the first or last dispensing operation that the dispensing mechanism is designed to perform where multiple operations are possible) has occurred. The component may be configured to perform only a single dispensing operation or multiple dispensing operations.

[0009] In the context of the present disclosure, the term "machine-readable" may refer to a structure or feature that carries information, preferably encoded information. In order to retrieve the information, the structure may be subjected to a reading procedure, preferably using a reader device. For example, the structure may be scanned by a reader device. The reader device may be an optical reader, for example using a light source such as a monochromatic light source, preferably based on a semiconductor (such as an LED or a semiconductor laser) for a scanning procedure. The light may be visible light and / or have a specific color, such as red. In order to retrieve information from the structure, a decoding procedure may be required. In other words, without the decoding procedure, the information cannot be retrieved. The decoding procedure may be executed in the reader device or in a processor device (e.g., a workstation, a server, or a PC) operably connected to the reader device. The decoded information may be displayed to the user on a display.

[0010] By the assembly further described above, a component for a drug delivery device is provided, which enables, for example, due to the visibility or invisibility of the second information feature and / or due to the first information feature to clearly and quickly detect and / or distinguish between a ready-to-dispense state and a dispensed state. Since the first information feature can be coupled to the cap, the distinction is even possible when the cap has been removed. Due to the machine readability of the first information feature, and preferably also due to the machine readability of the second information feature, even larger amounts of drug delivery devices can be quickly and reliably checked. This greatly reduces the risk of attempting to use or reuse the assembly in the dispensed state.

[0011] In a preferred embodiment, the encoded first content of the first information feature may be indicative of a first status of the allocating authority.

[0012] In a preferred embodiment, the second information feature may be indicative of a second status of the dispensing mechanism.

[0013] Thus, based on the information content of the information feature, it can be determined, for example, whether a component has been used.

[0014] In a preferred embodiment, the second information feature may have an encoded second content, wherein the second information feature is preferably machine readable to retrieve the second content from the second information feature.

[0015] Due to the machine readability of the second information feature, even a larger number of drug delivery devices can be checked quickly and reliably. This significantly reduces the risk of using a drug delivery device in an already dispensed condition.

[0016] In a preferred embodiment, the encoded first content of the first information feature may indicate a first status of the allocating authority, and / or the encoded second content of the second information feature may indicate a second status of the allocating authority.

[0017] Therefore, based on the information content of the information feature, it can be determined whether the component has been used. However, in order to obtain the corresponding information, a decoding procedure may have to be performed.

[0018] In a preferred embodiment, the assembly may include a movable member. The second information feature may be located on the movable member. When the dispensing mechanism is in the first state, the movable member may be in a first position, for example, relative to the housing. When the dispensing mechanism is in the second state, the movable member may be in a second position, for example, relative to the housing. The first position may be different from the second position. When dispensing liquid drug contents from the reservoir in a dispensing operation and / or after the dispensing operation has been completed, the movable member may be configured to move from the first position or may move to the second position. The movable member may be a member of the dispensing mechanism that moves during the dispensing operation and / or a member that moves after the dispensing operation has been completed. In the first position of the movable member, the second information feature may be covered by a preferably opaque housing. In the second position, the movable member may be visible, for example because it protrudes from the housing or because it is aligned with a window or window portion disposed in the housing.

[0019] By providing the second information feature on the movable member, for example by affixing the second information feature to the member, it can be ensured that the second information feature is only visible when the dispensing operation has been completed.

[0020] In a preferred embodiment, the movable member may be a plunger configured to push the liquid drug content out of the reservoir toward the distal dispensing end of the assembly during a dispensing operation. The plunger movement may force the liquid drug to flow out of the dispensing end. The housing may include a window portion. The second information feature and / or the plunger may be visible through the window portion in the second state of the dispensing mechanism and may not be visible through the window portion in the first state of the dispensing mechanism. The plunger may be part of the dispensing mechanism.

[0021] If the second information feature is located on the plunger, it is easily visible to the user and / or can be reliably read in the second state.

[0022] In a preferred embodiment, the movable member is a needle cover. The needle cover may be arranged to preferably cover the needle of the assembly after the dispensing operation has been completed. The needle cover may be movably connected to the housing and / or be part of the housing unit. In a first state, the needle cover may protrude from the housing. Movement of the needle cover towards the housing may initiate the dispensing operation. The needle cover may be arranged to move relative to the housing and / or enter a second position, for example by a spring, after the dispensing operation has been completed. During dispensing, the needle may be displaced relative to the housing. Preferably, the needle cover covers the needle at least after the dispensing operation has been completed and the assembly has been removed from the user. In this position, the needle cover may protrude further from the housing than before the injection begins.

[0023] One advantage of the needle cover is that the needle is protected from damage and the user is protected from injuries caused by inadvertent contact with the needle. Preferably, the needle cover performs this function in the ready-to-dispense state and / or in the dispensed state. By attaching a second information feature to the needle cover, two effects can be combined. On the one hand, it is achieved that the second information feature is only visible in the second state when the component is in the dispensed state, for example, because the needle cover protrudes further from the housing after the operation has been completed than in the first state. On the other hand, it is ensured that the user is protected from needle sticks and / or punctures in the second state. The needle cover is preferably not moved into the second position before the component is lifted off the target surface (e.g. a skin part).

[0024] In a preferred embodiment, the movable member may be a syringe or a cartridge. The syringe may be provided with a needle. The syringe may be a pre-filled syringe. The cartridge may be needle-free and moved into fluid communication with the needle during a dispensing operation.

[0025] In a preferred embodiment, the movable member can be a trigger member, which is configured to be actuated to trigger or start the dispensing operation. In order to trigger the dispensing operation, the trigger member can move away from the initial position relative to the housing, for example, move into the first position. When the pressure on the trigger member is released, the trigger member can be moved back to the second position, for example, by the trigger member spring, toward and preferably beyond the initial position. In the second position, the trigger member can protrude further from the housing than in the initial position. In that area of ​​the trigger member that is now uncovered due to no longer being covered by the housing, the second information feature can be located. The trigger member can be a trigger button.

[0026] In a preferred embodiment, the needle cover may serve as the triggering member.

[0027] In a preferred embodiment, the first information feature may be permanently modified when the cap is removed (e.g. by detaching the cap from the housing). Thus, after the cap has been removed, the encoded first content may no longer be retrievable from the modified first information feature, preferably even if the cap is reattached to the housing.

[0028] Reattaching the cap to the housing after a dispensing operation may falsely give the impression that the assembly is still in a ready-to-dispense condition. By permanently modifying the first information feature, e.g. by at least partially destroying the first information feature, e.g. by tearing off a label with the feature thereon, or completely when removing the cap, an erroneous assessment of the current state of the device can be avoided. Unreadability may be an (additional) indicator of the state of the assembly.

[0029] In a preferred embodiment, the assembly may comprise an information carrier connected to the cap and / or the housing unit, wherein the first information feature is preferably at least partially or completely located on the information carrier. The information carrier, for example configured as a ring, may establish the connection between the cap and the housing. Thus, it may serve as a connector.

[0030] Affixing the first information feature to the information carrier is less expensive than, for example, engraving or etching the first information feature into the surface of the cap and / or the housing unit.

[0031] In a preferred embodiment, the information carrier may be a seal.

[0032] The information carrier can in this way be used to seal the interface between cap and housing unit when the cap is connected to the housing unit.

[0033] In a preferred embodiment, at least one of the first information feature and the second information feature, or both information features, may comprise or be a two-dimensional barcode.

[0034] Barcodes can help eliminate the possibility of human error during information retrieval. Barcode scanning is fast and reliable. In addition, using a barcode system reduces training time for personnel responsible for inspecting drug delivery devices.

[0035] In a preferred embodiment, at least one of the first information feature and the second information feature, or both information features, may comprise or be a QR code.

[0036] QR codes can be scanned using a smartphone or any other mobile phone with a scanning function. QR codes are versatile and can encode almost all types of data, such as numeric data, alpha data, special data, and binary data. In addition, they can be scanned extremely quickly, which is particularly beneficial when a large number of drug delivery devices need to be scanned.

[0037] In a preferred embodiment, the assembly may be an autoinjector. The autoinjector may include a drive spring, which may be part of a dispensing mechanism, for example to move a plunger relative to a housing. The autoinjector may be a single-dose injector, i.e., a device that is used only once to deliver a single dose. Here, information about the current state of the mechanism is particularly advantageous.

[0038] Autoinjectors are easy to use and are ideal for self-administration by patients or by untrained personnel. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] Embodiments will now be described, by way of example only, with reference to the accompanying drawings, in which:

[0040] Figure 1A is a schematic side view of an autoinjector according to a first embodiment of the present invention, wherein a cap is attached to a housing unit of the autoinjector;

[0041] Figure 1B yes Figure 1A A schematic side view of an automatic injector with the cap removed from the housing unit;

[0042] Figure 2A is a schematic side view of an autoinjector according to a second embodiment of the present invention, wherein a cap is attached to a housing unit of the autoinjector;

[0043] Figure 2B yes Figure 2A A schematic side view of an automatic injector with the cap removed from the housing unit;

[0044] Figure 3A is a schematic side view of a housing unit of an automatic injector according to a third embodiment of the present invention in a ready-to-dispense condition;

[0045] Figure 3B yes Figure 3A A schematic side view of a housing unit in an allocated state;

[0046] Figure 4A is a schematic side view of a housing unit of an automatic injector according to a fourth embodiment of the present invention in a ready-to-dispense condition;

[0047] Figure 4B yes Figure 4A Schematic side view of a housing unit in an allocated state. DETAILED DESCRIPTION

[0048] As described herein, a drug delivery device can be configured to inject a medicament into a patient. For example, delivery can be subcutaneous, intramuscular, or intravenous. Such devices can be operated by a patient or a caregiver (such as a nurse or physician), and can include various types of safety syringes, pen injectors, or autoinjectors.

[0049] The autoinjector may comprise a drive spring which may be part of a dispensing mechanism, for example to move a plunger relative to a housing.The autoinjector may be a single-dose injector, for example a device that is used only once to deliver a single dose.

[0050] The device may include a cartridge-based system that requires piercing a sealed ampoule before use. The volume of the medicament delivered with these different devices may be in the range of about 0.5 ml to about 2 ml. Yet another device may include a large volume device ("LVD") or a patch pump that is configured to adhere to the patient's skin for a period of time (e.g., about 5, 15, 30, 60 or 120 minutes) to deliver a "large" volume of medicament (typically about 2 ml to about 10 ml).

[0051] In conjunction with specific medicaments, the currently described device can also be customized to operate within the required specification. For example, the device can be customized to inject medicaments in a certain period of time (for example, about 3 seconds to about 20 seconds for an automatic syringe, and about 10 minutes to about 60 minutes for a LVD). Other specifications can include low-level or minimum-level discomfort, or to certain conditions related to human factors, shelf life, validity period, biocompatibility, environmental factors, etc. Such changes may be caused by various factors (such as, for example, the viscosity range of the drug is about 3cP to about 50cP). Therefore, the drug delivery device will generally include a hollow needle with a size ranging from about 25 to about 31 gauges. Common sizes are 27 gauges and 29 gauges.

[0052] The delivery devices described herein may also include one or more automated functions. For example, one or more of needle insertion, medicament injection, and needle retraction may be automated. The energy for one or more automated steps may be provided by one or more energy sources. The energy source may include, for example, mechanical energy, pneumatic energy, chemical energy, or electrical energy. For example, a mechanical energy source may include a spring, a lever, an elastomer, or other mechanical mechanisms that store or release energy. One or more energy sources may be combined into a single device. The device may further include gears, valves, or other mechanisms that convert energy into movement of one or more components of the device.

[0053] One or more automatic functions of the automatic injector can be activated individually by an activation mechanism. Such an activation mechanism may include one or more of a button, a lever, a needle sleeve, or other activation components. The activation of the automatic function can be a one-step process or a multi-step process. That is, the user may need to activate one or more activation components in order to produce the automatic function. For example, in a one-step process, the user may press the needle sleeve against their body to cause the injection of the medicament. Other devices may require multi-step activation of the automatic function. For example, the user may be required to press a button and retract the needle shield to cause the injection.

[0054] In addition, activation of one automated function may activate one or more subsequent automated functions, thereby forming an activation sequence. For example, activation of a first automated function may activate at least two of needle insertion, medicament injection, and needle retraction. Some devices may also require a specific sequence of steps to cause one or more automated functions to occur. Other devices may operate in a series of independent steps.

[0055] Some delivery devices may include one or more functions of a safety syringe, a pen injector, or an auto-injector. For example, a delivery device may include a mechanical energy source configured to automatically inject a medicament (as typically found in an auto-injector) and a dose setting mechanism (as typically found in a pen injector).

[0056] According to some embodiments of the present disclosure, an exemplary assembly 1 for a drug delivery device is Figure 1A , Figure 1B , Figure 2A , Figure 2B , Figure 3A , Figure 3B , Figure 4A and Figure 4B Each exemplary assembly 1 is configured to inject a medicament into a patient. Figure 1A , Figure 1B , Figure 2A , Figure 2B , Figure 3A , Figure 3B , Figure 4A and Figure 4B The assembly 1 shown comprises: a housing unit 2, which generally comprises a housing for receiving a reservoir and a dispensing mechanism and / or elements of a dispensing mechanism (such as a plunger and / or a spring) configured to dispense liquid medicament contents from the reservoir in a dispensing operation; a cap 3 (in Figure 3A , Figure 3B , Figure 4A and Figure 4B ), the cap is releasably connected to the housing unit 2, wherein the cap 3 at least partially covers the distal dispensing end of the assembly 1 when connected to the housing unit 2, and the distal dispensing end is not covered when the cap 2 is disconnected from the housing; a first information feature 4 having a first encoded content (in Figure 3A , Figure 3B , Figure 4A and Figure 4B ), wherein the first information feature 4 is machine readable to retrieve the first content from the first information feature 4, wherein the encoded first content of the first information feature 4 indicates a first state of the distribution agency (in which the distribution agency is in a ready-to-distribute state); and the second information feature 5 (in Figure 1A , Figure 1B , Figure 2A and Figure 2B ), wherein the second information feature 5 indicates a second state of the dispensing mechanism (in which state the dispensing mechanism is in a dispensed condition). Furthermore, it is possible that the second information feature 5 has a coded second content, wherein the second information feature 5 is machine readable to retrieve the second content from the second information feature 5 and the coded second content indicates a second state of the dispensing mechanism, in which state the dispensing mechanism is in a dispensed condition. In addition to this, the housing unit 2 of the illustrated assembly 1 comprises a window portion 7. In addition Figure 3A and Figure 3B In addition to the embodiment, the window portion 7 can also be omitted.

[0057] In order to retrieve information or content from the corresponding machine-readable information feature, the structure can or must be subjected to a reading procedure, preferably using a reader device. For example, the structure can be scanned by a reader device. The reader device can be an optical reader, for example using a light source such as a monochromatic light source, preferably based on a semiconductor (such as an LED or a semiconductor laser) for a scanning procedure. The light can be visible light and / or have a specific color, such as red. In order to retrieve information from the structure, a decoding procedure may be required. In other words, without the decoding procedure, the information cannot be retrieved. The decoding procedure can be executed in the reader device or in a processor device (e.g., a workstation, a server or a PC) operably connected to the reader device. The decoded information can be displayed to the user on a display.

[0058] exist Figure 1A , Figure 1B , Figure 2A and Figure 2B In the example shown, the first information feature 4 is a QR code located on the information carrier. The information feature can be provided on a label or sticker attached to the information carrier, or can be integrated into the information carrier. The information carrier can be a rigid component or fit to the outer surface of the cap and / or the housing unit. However, other data representations (for example, other variants of preferably multidimensional, for example two-dimensional bar codes) are applicable to the information feature. For example, an information carrier configured as a ring can establish a connection between the cap 3 and the housing 2. Therefore, it can be used as a connector. Alternatively or additionally, the information carrier can be a seal. In this case, when the cap 3 is connected to the housing unit 2, the information carrier can be used to seal the intersection between the cap 3 and the housing unit 2.

[0059] Figure 1A and Figure 1B A schematic side view of an assembly 1 according to a first embodiment of the invention is shown, wherein a first information feature 4 is located on the surface of a cap 3. Figure 1A In , the cap 3 is attached to the housing unit 2, so that the first information feature 4 is visible and indicates the first state. Figure 1BIn the embodiment, the cap 3 is removed from the housing unit 2. If the user sets the cap 3 aside, the remaining components of the assembly 1 no longer contain any information that the dispensing mechanism of the assembly 1 is in the first state.

[0060] Figure 2A and Figure 2B A schematic side view of an assembly 1 according to a second embodiment of the invention is shown, wherein the first information feature 4 is partially located on the surface of the cap 3 and on the surface of the housing unit 2. Figure 2A In , the cap 3 is attached to the housing unit 2, so that the first information feature 4 is visible and indicates the first state. Figure 2B , the cap 3 is removed from the housing unit 2. Due to the removal of the cap 3 from the housing unit 2, the first information feature 4 is permanently destroyed, so that after the cap 3 has been removed, the encoded first content can no longer be retrieved from the destroyed first information feature 4. The sealing of the interface between the cap and the housing unit can be improved if the information carrier extends along an intermediate area between the cap and the housing unit, for example circumferentially (not explicitly shown).

[0061] In the previously described embodiments, the information carrier is preferably a conformable element, preferably a sticker or a label which is attached to the cap and / or the housing unit.

[0062] In another embodiment not depicted, the information carrier can be a rigid component (e.g., a sleeve) or an elastic component (e.g., a seal such as rubber). The information carrier can be arranged between the cap and the housing or housing unit, for example, clamped when the cap is directly connected to the housing or housing unit. The information carrier can be connected to the cap such as via a positive connection (e.g., a snap fit), and connected to the housing unit such as via a positive connection (e.g., a snap fit). The connection between the information carrier and the housing unit and between the cap and the information carrier can be designed to be incompatible. That is, preferably, the cap cannot be directly attached to the housing unit without an intermediate information carrier. In order to achieve the operability of the device, the information carrier may have to be removed from the housing unit. The connection between the information carrier and the housing and / or between the cap and the information carrier can be designed to be releasable only by modifying at least one of the connection features that are mutually engaged to establish the connection, so that after the connection has been released, it cannot be established again. Therefore, the information carrier and / or the information feature can indicate the drug contained in the reservoir. The label or sticker can be provided with an information feature, which can preferably be exclusively arranged on and / or connected to the information carrier.

[0063] Figure 3A and Figure 3B FIG. 2 shows a schematic side view of a housing unit 2 according to a third embodiment of the present invention. Figure 4A and Figure 4BAs shown, in the fourth embodiment of the present invention, the housing unit 2 of the third embodiment includes: a needle 9 for delivering liquid drug content from the reservoir in a dispensing operation; a needle cover 6, which protectively surrounds the needle 9; and a plunger 8, which pushes the liquid drug content out of the reservoir toward the distal dispensing end of the assembly 1 in a dispensing operation. The plunger is part of the dispensing mechanism.

[0064] Figure 3A A third embodiment of the first state of the dispensing mechanism is shown, wherein the dispensing mechanism is in a ready-to-dispense state. Figure 4A As shown, in the fourth embodiment in the first state of the dispensing mechanism, the second information feature 5 is not visible in the first state (i.e. when the dispensing operation has not yet been performed and / or started). However, the second information feature 5 in the second state is Figure 3B The third embodiment shown and Figure 4B Thus, the second feature 5 is only visible when the dispensing mechanism is in the dispensed condition after a dispensing operation.

[0065] exist Figure 3A , Figure 3B , Figure 4A and Figure 4B In the embodiment shown, the second information feature 5 is located on the movable member 6, 8, wherein when the dispensing mechanism is in the first state, the movable member 6, 8 is in a first position relative to the housing (eg Figure 3A and Figure 4A ), wherein, when the dispensing mechanism is in the second state, the movable members 6, 8 are in a second position relative to the housing (eg Figure 3B and Figure 4B ), and wherein the movable members 6, 8 move from the first position to the second position when liquid drug contents from the reservoir have been dispensed or have been dispensed from the reservoir in a dispensing operation.

[0066] exist Figure 3A and Figure 3B In the third embodiment shown, the movable member is a plunger 8. Figure 3B As shown, the second information feature 5 and the plunger 8 are visible through the window portion 7 in the second state of the dispensing mechanism, while Figure 3AAs shown, in the first state of the dispensing mechanism, it is not visible through the window portion 7. In this case, the reservoir (e.g., a syringe or cartridge) can be firmly held in the housing unit and does not move during the dispensing operation, which moves the plunger relative to the reservoir. Alternatively, the movable member can be a reservoir (e.g., a syringe or cartridge) that moves, for example, relative to a plunger that may be static to dispense its contents. The syringe can be provided with a needle 9. The syringe can be a prefilled syringe. The cartridge can be needle-free and moved to fluid communication with the needle 9 during the dispensing operation.

[0067] exist Figure 4A and Figure 4B In the fourth embodiment shown, the movable member is a needle cover 6 which is arranged to cover the needle 9 of the assembly 1 (in the case of a needle cover 6) after the dispensing operation has been completed and / or before it is started. Figure 4A and Figure 4B The needle cover 6 is movably connected to the housing and / or is part of the housing unit 2.

[0068] After the dispensing mechanism is activated, for example, via a trigger member, dispensing of the liquid drug content occurs via operation of the dispensing mechanism. After the dispensing operation has been completed and / or after the assembly has been lifted off the target surface (e.g., a skin portion), the needle cover 6 is moved distally, for example, due to a spring, from Figure 4A The first position shown (where the second information feature is not visible) is moved to Figure 4B The second position shown (wherein the second information feature 5 is visible on the needle cover 6). For example, the needle cover 6 can be used as a trigger member. In this case, the dispensing operation is triggered when the needle cover 6 is pressed onto the target surface and the housing unit moves relative to the needle cover. This movement can actuate the dispensing mechanism to perform the dispensing operation. Here, the needle cover 6 can protrude from the housing in the first state. The movement of the needle cover 6 towards the housing starts the dispensing operation and / or allows the needle to penetrate the target tissue or skin. The needle cover 6 is arranged to be movable, for example by a spring relative to the housing and / or into the second position after the dispensing operation has been completed. During dispensing, the needle 9 can be displaced relative to the housing or be stationary. As shown in FIG. Figure 4B As shown, at least after the dispensing operation has been completed and the assembly has been removed from the user, the needle cover 6 covers the needle 9. In this position, the needle cover 6 protrudes further from the housing than before the injection begins, thereby revealing the second information feature.

[0069] However, the needle cover need not be used as a trigger member as described above to start the dispensing operation. Instead, the assembly / device may include a separate trigger member (e.g., a trigger button) that can be moved by the user relative to the housing unit, such as being pressed to trigger the dispensing operation. In order to trigger the dispensing operation, the trigger member can be moved relative to the housing away from the initial position, such as moving into the first position. When, for example, the pressure applied by the user on the trigger member is released, the trigger member can be moved back to the second position, such as by a trigger member spring, toward and preferably beyond the initial position. In the second position, the trigger member can protrude further from the housing than in the initial position. In that area that is now uncovered, a second information feature 5 (not shown) can be positioned. Therefore, the trigger member can be used as a movable member with a second information feature (not shown). In addition to the needle cover or as a substitute for the needle cover, the trigger member can be provided with an information feature. Therefore, only one or more "second" information features can be present on the element that moves after the dispensing operation is started, during the dispensing operation, and / or after completion to indicate that the assembly is in a dispensed state.

[0070] In the above-mentioned embodiment, the second information feature 5 can be a QR code. However, the second information feature 5 can also include other types of, preferably machine-readable, data representations (eg, other variants of, preferably multi-dimensional, for example two-dimensional bar codes).

[0071] It should be noted that if Figure 3A and Figure 3B The third embodiment shown (particularly the arrangement of the second information feature 5) can be combined with Figure 1A , Figure 1B , Figure 2C and Figure 2B The first and second embodiments shown are combined (especially with the arrangement of the first information feature 4). The same applies to the fourth embodiment, such as Figure 4A and Figure 4B In addition, you can also Figure 4A and Figure 4B The plunger 8 of the fourth embodiment shown has an additional second information feature 5 added as in the third embodiment. Furthermore, the features disclosed in the introduction before describing the embodiments in conjunction with the drawings can of course be combined with the features described in conjunction with the exemplary embodiments shown in the drawings.

[0072] The terms "drug" or "medicament" are used synonymously herein and describe a pharmaceutical preparation containing one or more active pharmaceutical ingredients or a pharmaceutically acceptable salt or solvate thereof and optionally a pharmaceutically acceptable carrier. In the broadest sense, an active pharmaceutical ingredient ("API") is a chemical structure that has a biological effect on humans or animals. In pharmacology, a drug or medicament is used to treat, cure, prevent, or diagnose disease or to otherwise enhance physical or mental health. A drug or medicament may be used for a limited time or periodically for a chronic disease.

[0073] As described below, a drug or medicament may include at least one API or a combination thereof in various types of formulations for treating one or more diseases. Examples of APIs may include small molecules (having a molecular weight of 500 Da or less); polypeptides, peptides, and proteins (e.g., hormones, growth factors, antibodies, antibody fragments, and enzymes); carbohydrates and polysaccharides; and nucleic acids, double-stranded or single-stranded DNA (including naked and cDNA), RNA, antisense nucleic acids such as antisense DNA and RNA, small interfering RNA (siRNA), ribozymes, genes, and oligonucleotides. Nucleic acids may be incorporated into molecular delivery systems (such as vectors, plasmids, or liposomes). Mixtures of one or more drugs are also contemplated.

[0074] The drug or medicament can be contained in a primary package or "medicament container" adapted for a drug delivery device. The drug container can be, for example, a barrel, a syringe, a reservoir or other solid or flexible vessel, which is configured to provide a suitable chamber for storing (e.g., short-term or long-term storage) one or more drugs. For example, in some cases, the chamber can be designed to store the drug for at least one day (e.g., 1 day to at least 30 days). In some cases, the chamber can be designed to store the drug for about 1 month to about 2 years. Storage can be carried out at room temperature (e.g., about 20 ° C) or refrigerated temperature (e.g., from about -4 ° C to about 4 ° C). In some cases, the drug container can be or can include a dual-chamber barrel, which is configured to store two or more components (e.g., API and diluent, or two different drugs) of a pharmaceutical preparation to be administered separately, one of which is stored in each chamber. In this case, the two chambers of the dual-chamber barrel can be configured to allow mixing between two or more components before and / or during distribution to the human or animal body. For example, the two chambers may be configured so that they are in fluid communication with each other (e.g., via a conduit between the two chambers) and allow the user to mix the two components if desired before dispensing. Alternatively or additionally, the two chambers may be configured to allow mixing when dispensing the components into a human or animal body.

[0075] The medicine or medicament contained in the drug delivery device described herein can be used to treat and / or prevent many different types of medical diseases. The example of obstacle includes, for example, diabetes or complications related to diabetes (such as diabetic retinopathy), thromboembolic obstacles (such as deep vein or pulmonary thromboembolism). The further example of obstacle is acute coronary syndrome (ACS), angina pectoris, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and / or rheumatoid arthritis. The example of API and medicine is those as described in the following manual: such as Rote Liste 2014 (for example, but not limited to, main group (main group) 12 (antidiabetic drugs) or 86 (tumor drugs)) and Merck Index, the 15th edition.

[0076] Examples of APIs for treating and / or preventing type 1 or type 2 diabetes or complications associated with type 1 or type 2 diabetes include insulin (e.g., human insulin, or human insulin analogs or derivatives); glucagon-like peptide (GLP-1), GLP-1 analogs or GLP-1 receptor agonists, or analogs or derivatives thereof; dipeptidyl peptidase-4 (DPP4) inhibitors, or pharmaceutically acceptable salts or solvates thereof; or any mixture thereof. As used herein, the terms "analogs" and "derivatives" refer to polypeptides having a molecular structure that can be formally derived from the structure of a naturally occurring peptide (e.g., the structure of human insulin) by deleting and / or exchanging at least one amino acid residue present in a naturally occurring peptide and / or by adding at least one amino acid residue. The added and / or exchanged amino acid residues can be codable amino acid residues or other naturally occurring residues or purely synthetic amino acid residues. Insulin analogs are also referred to as "insulin receptor ligands." In particular, the term "derivative" refers to a polypeptide having a molecular structure that is formally derived from the structure of a naturally occurring peptide (e.g., the structure of human insulin), wherein one or more organic substituents (e.g., fatty acids) are bound to one or more amino acids. Optionally, one or more amino acids present in the naturally occurring peptide may have been deleted and / or replaced by other amino acids (including non-encodable amino acids), or amino acids (including non-encodable amino acids) have been added to the naturally occurring peptide.

[0077] Examples of insulin analogs are Gly(A21), Arg(B31), Arg(B32) human insulin (insulin glargine); Lys(B3), Glu(B29) human insulin (insulin glulisine); Lys(B28), Pro(B29) human insulin (insulin lispro); Asp(B28) human insulin (insulin aspart); human insulin in which the proline at position B28 is replaced by Asp, Lys, Leu, Val or Ala and in which the Lys at position B29 may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.

[0078] Examples of insulin derivatives are, for example, B29-N-myristoyl-des(B30) human insulin, Lys(B29)(N-tetradecanoyl)-des(B30) human insulin (insulin detemir, ); B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoylLysB28ProB29 human insulin; B28-N-palmitoyl-LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin; B30-N-palmitoyl-ThrB29LysB30 human insulin; B29-N-(N-palmitoyl-γ-glutamyl)-des(B30) human insulin, B29-N-ω-carboxypentadecanoyl-γ-L-glutamyl-des(B30) human insulin (insulindegludec, ); B29-N-(N-lithocholyl-γ-glutamyl)-des(B30) human insulin; B29-N-(ω-carboxyheptadecanoyl)-des(B30) human insulin and B29-N-(ω-carboxyheptadecanoyl) human insulin.

[0079] Examples of GLP-1, GLP-1 analogs and GLP-1 receptor agonists are e.g. lixisenatide Exendin-4 Liraglutide (a 39-amino acid peptide produced by the salivary glands of the Gila monster) , Semaglutide, Taspoglutide, Albiglutide , Dulaglutide , rExendin-4, CJC-1134-PC, PB-1023, TTP-054, Langelatide / HM-11260C, CM-3, GLP-1Eligen, ORMD-0901, NN-9924, NN-9926, NN-9927, Nodexen, Viador-GLP-1, CVX-096, ZYOG-1, ZYD-1, GSK-2374697, DA-3091, MAR-701, MAR709, ZP-2929, ZP-3022, TT-401, BHM-034. MOD-6030, CAM-2036, DA-15864, ARI-2651, ARI-2255, Exenatide-XTEN, and Glucagon-Xten.

[0080] Examples of oligonucleotides are: Mipomersen sodium , which is a cholesterol-reducing antisense therapeutic for the treatment of familial hypercholesterolemia.

[0081] Examples of DPP4 inhibitors are Vildagliptin, Sitagliptin, Denagliptin, Saxagliptin, Berberine.

[0082] Examples of hormones include pituitary hormones or hypothalamic hormones or regulatory activity peptides and their antagonists, such as gonadotropins (follicle-stimulating hormone, luteinizing hormone, chorionic gonadotropin, tocopherol), somatropine (growth hormone), desmopressin, terlipressin, gonadorelin, triptorelin, leuprorelin, buserelin, nafarelin and goserelin.

[0083] Examples of polysaccharides include glucosaminoglycanes, hyaluronic acid, heparin, low molecular weight heparin or ultra low molecular weight heparin or derivatives thereof, or sulfated polysaccharides (e.g., polysulfated forms of the above polysaccharides), and / or pharmaceutically acceptable salts thereof. An example of a pharmaceutically acceptable salt of polysulfated low molecular weight heparin is enoxaparin sodium. An example of a hyaluronic acid derivative is Hylan G-F20 , which is a sodium hyaluronate.

[0084] As used herein, the term "antibody" refers to an immunoglobulin molecule or an antigen binding portion thereof. Examples of antigen binding portions of immunoglobulin molecules include F (ab) and F (ab') 2 fragments, which retain the ability to bind antigens. The antibody can be a polyclonal antibody, a monoclonal antibody, a recombinant antibody, a chimeric antibody, a deimmunized antibody or a humanized antibody, a fully human antibody, a non-human (e.g., mouse) antibody or a single-chain antibody. In some embodiments, the antibody has effector functions and can fix complement. In some embodiments, the antibody has reduced or no ability to bind Fc receptors. For example, the antibody can be an isotype or subtype, an antibody fragment or a mutant, and the antibody does not support binding to Fc receptors, for example, it has a mutagenic or missing Fc receptor binding region. The term antibody also includes antigen binding molecules based on tetravalent bispecific tandem immunoglobulins (TBTI) and / or dual variable region antibody-like binding proteins with cross-binding region orientation (CODV).

[0085] The term "fragment" or "antibody fragment" refers to a polypeptide (e.g., antibody heavy chain and / or light chain polypeptide) derived from an antibody polypeptide molecule, which does not include a full-length antibody polypeptide, but still includes at least a portion of a full-length antibody polypeptide capable of binding an antigen. Antibody fragments may include cleavage portions of full-length antibody polypeptides, although the term is not limited to such cleavage fragments. Antibody fragments that can be used in the present invention include, for example, Fab fragments, F(ab')2 fragments, scFv (single-chain Fv) fragments, linear antibodies, monospecific or multispecific antibody fragments (e.g., bispecific, trispecific, tetraspecific and multispecific antibodies (e.g., double-chain antibodies, three-chain antibodies, four-chain antibodies)), monovalent or multivalent antibody fragments (e.g., bivalent, trivalent, tetravalent and multivalent antibodies), mini antibodies, chelated recombinant antibodies, three antibodies or double antibodies, intracellular antibodies, nano antibodies, small modular immunopharmaceuticals (SMIP), binding domain immunoglobulin fusion proteins, camelized antibodies and antibodies containing VHH. Other examples of antigen-binding antibody fragments are known in the art.

[0086] The term "complementarity determining region" or "CDR" refers to short polypeptide sequences within the variable region of both heavy and light chain polypeptides that are primarily responsible for mediating specific antigen recognition. The term "framework region" refers to amino acid sequences within the variable region of both heavy and light chain polypeptides that are not CDR sequences and are primarily responsible for maintaining the correct positioning of the CDR sequences to allow antigen binding. Although the framework region itself is generally not directly involved in antigen binding, as is known in the art, certain residues in the framework region of certain antibodies may be directly involved in antigen binding or may affect the ability of one or more amino acids in the CDR to interact with the antigen.

[0087] Examples of antibodies are anti-PCSK-9 mAb (eg, Alirocumab), anti-IL-6 mAb (eg, Sarilumab), and anti-IL-4 mAb (eg, Dupilumab).

[0088] Pharmaceutically acceptable salts of any API described herein are also contemplated for use in a drug or medicament in a drug delivery device.Pharmacologically acceptable salts are, for example, acid addition salts and basic salts.

[0089] Those skilled in the art will appreciate that modifications (additions and / or removals) may be made to the various components of the API, formulations, apparatus, methods, systems and embodiments described herein without departing from the full scope and spirit of the invention, and that the invention encompasses such modifications and any and all equivalents thereof.

Claims

1. A component (1) for a drug delivery device, the component (1) comprising: a housing unit (2) comprising a housing for receiving a reservoir and a dispensing mechanism configured to dispense liquid medicament contents from the reservoir in a dispensing operation, a cap (3) releasably connected to the housing unit (2), the cap (3) at least partially covering a distal dispensing end of the assembly (1) when connected to the housing unit (2), the distal dispensing end being uncovered when the cap (3) is disconnected from the housing unit, a first information feature (4) having an encoded first content, wherein the first information feature (4) is machine-readable for retrieving the first content from the first information feature (4), The second information feature (5), where The first information feature (4) is visible and / or machine-readable when the cap (3) is connected to the housing unit (2) and can be removed from the housing unit (2) together with the cap (3) or become unreadable when the cap (3) is disconnected from the housing unit (2), wherein the dispensing mechanism has two different states, namely a first state in which the dispensing mechanism is in a ready-to-dispense state and a second state in which the dispensing mechanism is in a dispensed state, wherein the second information feature (5) is not visible in the first state and is visible in the second state, The assembly (1) comprises a movable member, wherein the second information feature (5) is located on the movable member, wherein the movable member is in a first position when the dispensing mechanism is in the first state, wherein the movable member is in a second position when the dispensing mechanism is in the second state, wherein the movable member is configured to move from the first position to the second position after the dispensing operation is completed, and wherein the movable member is a trigger member which triggers the dispensing operation when actuated.

2. The assembly (1) according to claim 1, wherein The encoded first content of the first information feature (4) is indicative of the first status of the allocation mechanism, and wherein the second information feature (5) is indicative of the second status of the allocation mechanism.

3. The assembly (1) according to claim 1, wherein The second information feature (5) has an encoded second content, and wherein the second information feature (5) is machine-readable for retrieving the second content from the second information feature (5).

4. Assembly (1) according to claim 3, wherein The encoded first content of the first information feature (4) is indicative of the first status of the allocation mechanism, and wherein the encoded second content of the second information feature (5) is indicative of the second status of the allocation mechanism.

5. The assembly (1) according to claim 1, wherein The movable member is a needle cover (6) arranged to cover a needle (9) of the assembly (1).

6. Assembly (1) according to any one of claims 1 to 5, wherein When the cap (3) is removed, the first information feature (4) is permanently modified, so that after the cap (3) has been removed, the encoded first content can no longer be retrieved from the modified first information feature.

7. The assembly (1) according to any one of claims 1 to 5, wherein The assembly (1) comprises an information carrier connected to the cap (3) and / or the housing unit (2), wherein the first information feature (4) is located on the information carrier.

8. Assembly (1) according to claim 7, wherein The information carrier is a seal.

9. Assembly (1) according to any one of claims 1 to 5, wherein: At least one of the first information feature (4) and the second information feature (5) is a two-dimensional barcode.

10. The assembly (1) according to any one of claims 1 to 5, wherein: At least one of the first information feature (4) and the second information feature (5) is a QR code.

11. The assembly (1) according to any one of claims 1 to 5, wherein: The assembly (1) is an automatic injector comprising the reservoir containing a liquid drug.

12. The assembly (1) according to claim 8, wherein The information carrier is configured in a ring shape.

13. The assembly (1) according to claim 8, wherein The information carrier is configured to establish a connection between the cap (3) and the housing unit (2).

14. Assembly (1) according to claim 11, wherein The autoinjector is a single-dose injector, ie a device that is used only once to deliver a single dose.

15. Assembly (1) according to any one of claims 1 to 5, wherein The first information feature (4) is partially located on the outer surface of the cap (3) and on the outer surface of the housing unit (2).